ストックスクリーナーアプリを入手
93.35
2.63%
-2.52
アフターアワーズ：
93.35
前日終値:
$95.87
開ける：
$95.9
24時間の取引高:
286.91K
Relative Volume:
0.61
時価総額：
$6.22B
収益：
-
当期純損益:
$-224.29M
株価収益率:
-23.94
EPS:
-3.9
ネットキャッシュフロー:
$-185.06M
1週間 パフォーマンス:
-6.01%
1か月 パフォーマンス:
+11.96%
6か月 パフォーマンス:
+39.91%
1年 パフォーマンス:
-0.79%
1日の値動き範囲:
$91.71
$95.90
1週間の範囲:
$89.02
$99.81
52週間の値動き範囲:
$55.53
$104.90
Nuvalent Inc Stock (NUVL) Company Profile
NUVL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
93.35 | 6.97B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.50B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-16 | 再開されました | Stifel | Buy |
| 2025-10-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-09-04 | 再開されました | Guggenheim | Buy |
| 2025-09-03 | 開始されました | Raymond James | Outperform |
| 2025-08-19 | 開始されました | Piper Sandler | Overweight |
| 2025-03-14 | アップグレード | UBS | Neutral → Buy |
| 2024-12-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-10-24 | 開始されました | UBS | Neutral |
| 2024-08-29 | 開始されました | Barclays | Overweight |
| 2024-04-17 | 開始されました | Jefferies | Buy |
| 2024-04-01 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | 再開されました | Guggenheim | Buy |
| 2024-02-23 | 開始されました | Robert W. Baird | Outperform |
| 2023-09-27 | 開始されました | Stifel | Buy |
| 2023-08-08 | 開始されました | SVB Securities | Market Perform |
| 2023-07-24 | 開始されました | Guggenheim | Buy |
| 2023-01-18 | 開始されました | Wedbush | Outperform |
| 2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
すべてを表示
Nuvalent Inc (NUVL) 最新ニュース
What momentum indicators show for Nuvalent Inc. stockDividend Hike & Momentum Based Trading Ideas - newser.com
How Nuvalent Inc. stock trades during market volatilityGold Moves & High Accuracy Investment Signals - newser.com
Can Nuvalent Inc. stock maintain growth trajectory2025 Price Action Summary & Weekly High Return Forecasts - newser.com
Nuvalent’s Zidesamtinib Study: A Potential Game-Changer in Cancer Treatment - MSN
Why Nuvalent Inc. stock attracts high net worth investors2025 Sector Review & Reliable Price Breakout Signals - fcp.pa.gov.br
Will Nuvalent Inc. bounce back from current supportWeekly Trade Analysis & Accurate Buy Signal Alerts - newser.com
Why Nuvalent Inc. stock remains resilientQuarterly Profit Report & Free Weekly Watchlist of Top Performers - newser.com
Will Nuvalent Inc. stock rally after Fed decisionsGlobal Markets & Daily Chart Pattern Signal Reports - newser.com
Using economic indicators to assess Nuvalent Inc. potential2025 Fundamental Recap & Smart Allocation Stock Tips - newser.com
Why Nuvalent Inc. stock is trending among retail tradersJuly 2025 Trends & Long-Term Capital Growth Strategies - newser.com
Can volume confirm reversal in Nuvalent Inc.Trade Volume Summary & Risk Controlled Stock Pick Alerts - newser.com
Custom strategy builders for tracking Nuvalent Inc.Dip Buying & Daily Market Momentum Tracking - newser.com
What data driven models say about Nuvalent Inc.’s futureFed Meeting & Daily Chart Pattern Signal Reports - newser.com
Is Nuvalent Inc. stock a bargain at current levelsGold Moves & Long-Term Growth Portfolio Plans - newser.com
Nuvalent to present zidesamtinib patient data at lung cancer conference By Investing.com - Investing.com Nigeria
Why analysts remain bullish on Nuvalent Inc. stockWeekly Investment Report & Verified Stock Trade Ideas - newser.com
Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer - Lelezard
Statistical indicators supporting Nuvalent Inc.’s strengthMarket Activity Summary & Trade Opportunity Analysis - newser.com
Nuvalent: Interesting Product, But Aggressive Valuation (NASDAQ:NUVL) - Seeking Alpha
Nuvalent to present zidesamtinib patient data at lung cancer conference - Investing.com
Nuvalent unveils patient outcomes data at key cancer conference - Traders Union
Nuvalent (NASDAQ: NUVL) to present ARROS-1 PRO and pivotal efficacy/safety at IASLC ASCO - Stock Titan
Published on: 2025-11-04 11:51:01 - newser.com
How risky is Nuvalent Inc. stock now2025 Volume Leaders & Verified Momentum Stock Watchlist - newser.com
Can Nuvalent Inc. stock outperform in 2025 bull market2025 Retail Activity & Reliable Trade Execution Plans - newser.com
Nuvalent Inc (NUVL) 財務データ
収益
当期純利益
現金流量
EPS
Nuvalent Inc (NUVL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Noci Darlene | Chief Development Officer |
Oct 30 '25 |
Sale |
102.92 |
4,000 |
411,661 |
48,034 |
| Miller Deborah Ann | Chief Legal Officer |
Oct 30 '25 |
Option Exercise |
6.89 |
21,800 |
150,202 |
70,886 |
| Miller Deborah Ann | Chief Legal Officer |
Oct 30 '25 |
Sale |
103.16 |
21,800 |
2,248,943 |
49,086 |
5.44%
0.70%
大文字化:
|
ボリューム (24 時間):